References
1. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27 (7-8): 832-40.
2. Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring–cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions.Pharmacoepidemiol Drug Saf 1997; 6 Suppl 3 : S71-7.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA 1998; 279 (15): 1200-5.
4. Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients: A systematic review of the prospective and retrospective studies. Bandolier Extra 2002; (June 2002): 1-15.
5. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24 (2): 46-54.
6. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008; 42 (7): 1017-25.
7. World Health Organisation. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Geneva: World Health Organization; 2002.
8. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356 (9237): 1255-9.
9. Council for International Organisations of Medical Sciences (CIOMS). Current challenges in pharmacovigilance: pragmatic approaches. Report of CIOMS working group V. Geneva, 2001.
10. University of North Carolina Libraries. Low and middle income countries - LMIC filters (PubMed). http://guides.lib.unc.edu/ld.php?content_id=258985.
11. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]: The Cochrane Collaboration; 2011.
12. Smyth RM, Gargon E, Kirkham J, et al. Adverse drug reactions in children–a systematic review. PLoS One 2012; 7 (3): e24061.
13. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52 (1): 77-83.
14. Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child 2009;94 (9): 724-8.
15. Khan LM. Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay–a systematic review. Eur J Clin Pharmacol 2013;69 (12): 1985-96.
16. Angamo MT, Chalmers L, Curtain CM, Bereznicki LR. Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors.Drug Saf 2016; 39 (9): 847-57.
17. Miguel A, Azevedo LF, Araujo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2012; 21 (11): 1139-54.
18. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf 2007;2 (1): 79-87.
19. Martins ACM, Giordani F, Rozenfeld S. Adverse drug events among adult inpatients: a meta-analysis of observational studies.Journal of Clinical Pharmacy and Therapeutics 2014;39 (6): 609-20.
20. Hakkarainen KM, Hedna K, Petzold M, Hagg S. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions–a meta-analysis. PLoS One 2012; 7 (3): e33236.
21. Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm 2003; 60 (17): 1750-9.
22. Patel NS, Patel TK, Patel PB, Naik VN, Tripathi CB. Hospitalizations due to preventable adverse reactions-a systematic review. Eur J Clin Pharmacol 2017; 73 (4): 385-98.
23. Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 2007;41 (9): 1411-26.
24. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007; 63 (2): 136-47.
25. Saedder EA, Brock B, Nielsen LP, Bonnerup DK, Lisby M. Identifying high-risk medication: a systematic literature review. Eur J Clin Pharmacol 2014; 70 (6): 637-45.
26. Tam VC, Knowles SR, Cornish PL, Fine N, Marchesano R, Etchells EE. Frequency, type and clinical importance of medication history errors at admission to hospital: a systematic review. CMAJ 2005;173 (5): 510-5.
27. Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2014;23 (5): 489-97.
28. Al Hamid A, Ghaleb M, Aljadhey H, Aslanpour Z. A systematic review of hospitalization resulting from medicine-related problems in adult patients. Br J Clin Pharmacol 2014; 78 (2): 202-17.
29. Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf 2007; 30 (5): 379-407.
30. Leendertse AJ, Visser D, Egberts AC, van den Bemt PM. The relationship between study characteristics and the prevalence of medication-related hospitalizations: a literature review and novel analysis. Drug Saf 2010; 33 (3): 233-44.
31. Jolivot PA, Hindlet P, Pichereau C, et al. A systematic review of adult admissions to ICUs related to adverse drug events. Crit Care 2014; 18 (6): 643.
32. Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol 2017; 73 (6): 759-70.
33. Mekonnen AB, Alhawassi TM, McLachlan AJ, Brien JE. Adverse Drug Events and Medication Errors in African Hospitals: A Systematic Review.Drugs Real World Outcomes 2018; 5 (1): 1-24.
34. Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 2018; 74 (6): 819-32.
35. Wolfe D, Yazdi F, Kanji S, et al. Incidence, causes, and consequences of preventable adverse drug reactions occurring in inpatients: A systematic review of systematic reviews. PLoS One2018; 13 (10): e0205426.
36. Oshikoya KA, Njokanma OF, Chukwura HA, Ojo IO. Adverse drug reactions in Nigerian children. Paediatric and Perinatal Drug Therapy 2007; 8 (2): 81-8.
37. Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 2008;65 (3): 396-406.
38. Bah M. Effets indésirables des médicaments dans le service de médecine interne de l’Hôpital du Point-G [Doctoral]. Bamako: Université de Bamako; 2006.
39. Soukho-Kaya A, Minta DK, Diarra MT, et al. Les effets indésirables des médicaments dans le service Médecine Interne C.H.U. du Point G.Mali Médical 2010; XXV (3): 10-4.
40. Oshikoya KA, Chukwura H, Njokanma OF, Senbanjo IO, Ojo I. Incidence and cost estimate of treating pediatric adverse drug reactions in Lagos, Nigeria. Sao Paulo Med J 2011; 129 (3): 153-64.
41. Tumwikirize WA, Ogwal-Okeng JW, Vernby A, Anokbonggo WW, Gustafsson LL, Lundborg SC. Adverse drug reactions in patients admitted on internal medicine wards in a district and regional hospital in Uganda. Afr Health Sci 2011; 11 (1): 72-8.
42. Kauffman YS, Connor SE, Jonkman LJ, et al. Retrospective Evaluation of Adverse Drug Reactions in a Central Hospital in Malawi.Enliven: Pharmacovigilance and Drug Safety 2014; 1 (4): 004.
43. Aderemi-Williams RI, Awodele O, Boyle CA. Adverse drug reactions amongst adult patients admitted in Lagos State University Teaching Hospital Lagos, Nigeria. Curr Drug Saf 2015; 10 (2): 136-44.
44. Ayetoro S. Evaluation of adverse drug reactions (ADRs) among in-patients admitted into the adult medical wards of a university teaching hospital in Nigeria. World Congress of Pharmacy and Pharmaceutical Sciences. Düsseldorf; 2015.
45. Ayetoro SO, Olagunju AO, Laiyemo KA. Evaluation of Adverse Drug Reactions Among In-Patients Admitted into the Adult Medical Wards of University of Ilorin Teaching Hospital, Nigeria. 14th annual meeting of International Society of Pharmacovigilance. Tianjin: Drug Safety; 2014. p. 841.
46. Mouton JP, Mehta U, Parrish AG, et al. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey. Br J Clin Pharmacol 2015;80 (4): 818-26.
47. Mouton JP, Njuguna C, Kramer N, et al. Adverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa. Medicine (Baltimore) 2016;95 (19): e3437.
48. Russom M, Tesfai D, Elias M, et al. Adverse Drug Reactions among Patients Admitted to Eritrean Hospitals: Prevalence Causes and Risk Factors a prospective analysis of 5848 patients. International Journal of Pharmacovigilance 2017; 2 (1): 1-7.
49. Angamo MT, Chalmers L, Curtain CM, Yilma D, Bereznicki L. Mortality from adverse drug reaction-related hospitalizations in south-west Ethiopia: A cross-sectional study. J Clin Pharm Ther 2018;43 (6): 790-8.
50. Angamo MT, Curtain CM, Chalmers L, Yilma D, Bereznicki L. Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross-sectional study. PLoS One 2017;12 (10): e0186631.
51. Makiwane M, Decloedt E, Chirehwa M, Rosenkranz B, Kruger M. Adverse Drug Reactions in Paediatric In-Patients in a South African Tertiary Hospital. J Trop Pediatr 2019; 65 (4): 389-96.
52. Adedapo ADA, Adedeji WA, Adedapo IA, Adedapo KS. Cohort study on adverse drug reactions in adults admitted to the medical wards of a tertiary hospital in Nigeria: Prevalence, incidence, risk factors and fatality. Br J Clin Pharmacol 2021; 87 (4): 1878-89.
53. Mouton JP, Fortuin-de Smidt MC, Jobanputra N, et al. Serious adverse drug reactions at two children’s hospitals in South Africa. BMC Pediatr 2020; 20 (1): 3.
54. International drug monitoring: the role of the hospital, report of a WHO meeting held in Geneva from 18 to 23 November 1968, 1969.
55. Jones JK. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Community Health 1982; 5 (2): 58-67.
56. World Health Organisation, Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf (accessed 28 March 2021.
57. Temple ME, Robinson RF, Miller JC, Hayes JR, Nahata MC. Frequency and preventability of adverse drug reactions in paediatric patients.Drug Saf 2004; 27 (11): 819-29.
58. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27 (6): 538.
59. Begaud B, Evreux JC, Jouglard J, Lagier G. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie 1985; 40 (2): 111-8.
60. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30 (2): 239-45.
61. Aronson JK, Ferner RE. Clarification of terminology in drug safety.Drug Saf 2005; 28 (10): 851-70.
62. Benkirane R, Soulaymani-Bencheikh R, Khattabi A, et al. Assessment of a new instrument for detecting preventable adverse drug reactions.Drug Saf 2015; 38 (4): 383-93.
63. Ampadu HH, Hoekman J, de Bruin ML, et al. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase(R). Drug Saf 2016;39 (4): 335-45.
64. Thurmann PA. Methods and systems to detect adverse drug reactions in hospitals. Drug Saf 2001; 24 (13): 961-8.
65. Montane E, Castells X. Epidemiology of drug-related deaths in European hospitals: A systematic review and meta-analysis of observational studies. Br J Clin Pharmacol 2021: 14799.
66. Wester K, Jonsson AK, Spigset O, Druid H, Hagg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008; 65 (4): 573-9.
67. Brennan AT, Davies MA, Bor J, et al. Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa? AIDS 2017; 31 (1): 147-57.
68. Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS 2019; 33 (9): 1455-65.